Kevin Zablonski/LinkedIn, William Archibald/LinkedIn
Jul 23, 2026, 19:25
William Archibald: Key Takeaways on VTE Cost-Effectiveness and Cancer Associated Thrombosis from ISTH 2026
William Archibald, Assistant Professor of Medicine at Wilmot Cancer Institute, shared a post on LinkedIn:
“Back home in Rochester from a very successful International Society on Thrombosis and Haemostasis (ISTH) 2026 where Kevin Zablonski and I presented our work on the cost effectiveness of apixaban for extended prevention in provoked VTE (clinical benefit and cost effective from Medicare perspective!)
Look out for our highlights of ISTH 2026 coming to OncUpdates soon for practice changes in cancer associated thrombosis and thrombocytopenia
Looking forward to ISTH 2027 in Vancouver.”
Stay updated with Hemostasis Today.
-
Sep 11, 2026, 03:10Chris Oung: Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk
-
Sep 10, 2026, 21:33J. Meireles-Brandao: Lp(a)HORIZON and the Role of Inflammation in ASCVD
-
Sep 10, 2026, 21:31Alejandro González Veliz: Pregnancy is a Cardiovascular Stress Test
-
Sep 10, 2026, 21:30Tareq Abadl: Did You Know That the Type of Hemoglobin in Our Blood Changes Throughout Life?
-
Sep 10, 2026, 21:30Sumyea Kabir: Apheresis Awareness Day – One Donor, One Procedure, One Therapeutic Difference
-
Sep 10, 2026, 21:30Suhasini Sil: Excited to Share Our New Publication on HLA Beyond Histocompatibility
-
Sep 10, 2026, 21:29Michael Meneghini: Your Calves Are Not Just for Walking
-
Sep 10, 2026, 21:27One month until International Plasma Awareness Week – PPTA Europe
-
Sep 10, 2026, 21:26John Strouse: Supporting Research to Improve Lives in Sickle Cell Disease